This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

XL880

Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.

What XL880 Means in Everyday Medical Language

XL880 is another name for the drug Foretinib, which is also called MET/VEGFR-2 Inhibitor GSK1363089. This drug is designed to block certain enzymes, called kinases, that help cancer cells grow and spread. Two important enzymes it targets are c-Met and VEGFR-2. These enzymes not only support tumor growth but also help tumors create new blood vessels, which supply the tumor with nutrients and oxygen.

Why XL880 Can Matter in Cancer Care

Tumors need blood vessels to grow and spread. Drugs like XL880 that block the formation of new blood vessels (called antiangiogenesis agents) are an important area of cancer research. By targeting both c-Met and VEGFR-2 enzymes, XL880 may affect tumor growth in multiple ways. However, it is still an experimental drug, meaning it is not yet approved for routine cancer treatment and is mainly studied in clinical trials.

What Patients Might See or Hear About XL880

Patients may come across the name XL880 or its other names, Foretinib or MET/VEGFR-2 Inhibitor GSK1363089, in medical reports, research articles, or clinical trial information. It might be mentioned as a possible treatment option under study. Because the drug has several names, it can be confusing. It’s helpful to compare the wording carefully and ask your care team what it means for your specific situation.

Where XL880 Might Appear in Medical Information

XL880 may appear in clinical trial descriptions, research studies, or experimental treatment plans. It might also be listed in medical records or discussions if your care team is considering or studying its use. Since it is not an approved treatment, it is less likely to be part of routine care outside of research settings.

What XL880 Does Not Automatically Mean

Seeing the term XL880, Foretinib, or MET/VEGFR-2 Inhibitor GSK1363089 does not mean you have a specific diagnosis or that this drug is recommended or safe for you. It is an experimental drug, and its use depends on many factors. It is important not to assume XL880 is a standard or proven treatment based on the name alone.

Practical Questions to Ask Your Care Team

If XL880 comes up in your care, you might ask: What is XL880, and how might it relate to my treatment? Is it part of a clinical trial or experimental therapy? What are the potential benefits and risks? Are there approved treatments that might be better options? Understanding these points can help you make informed decisions.

How to Read XL880 in Context

Because XL880 has several names and is experimental, it’s important to consider the full context where it appears. Ask your care team to explain what it means in your specific medical report, treatment plan, or discussion. This helps avoid confusion and ensures you understand how it applies to your care.

Safety and Next Steps

This information is educational and does not replace medical advice. XL880 is not approved as a standard treatment and is mainly studied in clinical trials. If you see this term in your medical records or hear it mentioned, the safest next step is to ask your care team what it means for your individual situation and whether it is relevant to your care.

Sources

Public source information used for this glossary entry includes: